Amundi
SWTX

Amundi’s SpringWorks Therapeutics SWTX Stock Holding History

Amundi’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,772
Closed -$115K – 2073
2023
Q4 		$115K Hold
2,772
– – ﹤0.01% 1747
2023
Q3 		$62.9K Hold
2,772
– – ﹤0.01% 1837
2023
Q2 		$73K Hold
2,772
– – ﹤0.01% 1840
2023
Q1 		$68.6K Sell
2,772
-906
-25% -$26.5K ﹤0.01% 1823
2022
Q4 		$102K Buy
3,678
+1,000
+37% +$24.6K ﹤0.01% 1603
2022
Q3 		$75K Hold
2,678
– – ﹤0.01% 1604
2022
Q2 		$77K Buy
+2,678
New +$97.9K ﹤0.01% 1494

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Amundi's SWTX Position: Q1 2024 in Review

Amundi sold out of SpringWorks Therapeutics (SWTX) in Q1 2024, closing a stake of 2,772 shares — an estimated $115K sold.

Amundi first reported a position in SWTX in Q2 2022 and held it in 7 quarters. The position peaked at $115K in Q4 2023. 217 funds tracked by Wall St. Rank hold SWTX as of Q1 2024.

  • Amundi reported no remaining SpringWorks Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Amundi sold 2,772 SpringWorks Therapeutics shares in Q1 2024, an estimated $115K.
  • Amundi first reported a position in SpringWorks Therapeutics in Q2 2022 and held it in 7 quarters.
  • Amundi's SpringWorks Therapeutics position peaked at $115K in Q4 2023.
  • 217 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2024.

Based on Amundi's 13F filing for Q1 2024, filed 15 May 2024.